TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07098338: An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants With Locally Advanced or Metas

Sponsor: AstraZeneca · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 278 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$554,400

Rescue Site Savings

+$369,600

Unlock Full NCT07098338 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07098338 Rescue Dossier →